Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma Inc. (SILO) is a biopharmaceutical innovator developing novel therapies that combine traditional treatments with psychedelic research for conditions including PTSD and chronic pain. This dedicated news hub provides investors and researchers with essential updates on the company's clinical progress, strategic partnerships, and therapeutic advancements.
Access centralized, reliable information about Silo Pharma's pipeline developments, including its intranasal SPC-15 formulation for stress disorders and SP-26 implant technology for pain management. The page aggregates official press releases, research milestones, and financial disclosures while maintaining strict compliance with financial reporting standards.
Key updates cover clinical trial phases, intellectual property developments, university research collaborations, and regulatory filings. All content is verified through primary sources to ensure accuracy and timeliness for stakeholders tracking the company's progress in psychedelic-assisted therapeutics and advanced drug delivery systems.
Bookmark this page for streamlined access to Silo Pharma's latest announcements. For comprehensive tracking of the company's innovative approach to CNS disorder treatments, consider subscribing to Stock Titan's news alerts.
Silo Pharma (Nasdaq: SILO) has announced a significant milestone in the development of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). The company has initiated first dosing in an IND-enabling GLP-compliant toxicology and toxicokinetics study.
Following a successful pre-IND meeting with the FDA in September 2024, Silo is pursuing the 505(b)(2) regulatory pathway for SPC-15's approval. This pathway is designed to potentially reduce clinical development timelines and costs. The current studies, if successful, will provide the final preclinical data required for submitting an IND application and advancing to first-in-human clinical trials.
Silo Pharma (Nasdaq: SILO) has secured a new U.S. patent (projected number 12,239,614) for its lead asset SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females,' will be issued on March 4, 2025.
This patent builds upon previously issued U.S. Patent 11,491,120 from November 2022, adding new claims and strengthening the company's intellectual property portfolio. The development supports Silo's collaborative research with Columbia University and advances their efforts toward clinical trials for SPC-15.
Silo Pharma (NASDAQ: SILO) has filed a new provisional patent application with the USPTO for its lead asset SPC-15, expanding its intellectual property portfolio. The patent covers a dual-action method and composition for treating stress-induced psychiatric disorders.
A preclinical study demonstrated that the combination of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, with an N-methyl-D-aspartate receptor (NMDAR) antagonist showed significant improvements in behavioral outcomes and reduced severe stress-induced conditions. This technology was originally licensed through a collaboration with Columbia University.
The company has also recently filed a separate expanded provisional patent application focusing on chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
Silo Pharma (NASDAQ: SILO) reported positive initial results from its ongoing study of SP-26, a novel ketamine extended-release rod implant designed for chronic pain and fibromyalgia treatment. The non-GLP small animal testing, which began in December 2024, showed no serious side effects or discomfort following implantation in early January 2025.
The SP-26 implant is being developed as a self-administered, non-opioid therapeutic. The study is currently in the final stages of Absorption, Distribution, Metabolism, and Excretion (ADME) testing, with final safety and pharmacokinetic reports expected in March 2025.
Silo Pharma (NASDAQ: SILO) has filed a provisional patent application with the USPTO for its lead asset SPC-15, targeting treatments for stress-induced psychiatric disorders, including PTSD. The patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors (NMDARs) and serotonin type IV receptors (5-HT4Rs) to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.
This filing enhances Silo's intellectual property portfolio for SPC-15 technology, which was originally licensed through a collaboration with Columbia University. The exclusive agreement grants Silo global rights to develop, manufacture, and commercialize SPC-15.
Silo Pharma (NASDAQ: SILO) has received a Notice of Allowance from the USPTO for patent application 17/954,864, titled 'Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.' This patent, expected to be formally issued within 90 days, will strengthen protection for SPC-15, the company's lead asset targeting post-traumatic stress disorder (PTSD) through intranasal delivery.
The patent includes new claims to U.S. Patent 11,491,120, which was issued to Silo in February 2023. The company holds an exclusive license agreement with Columbia University for global development, manufacturing, and commercialization rights of SPC-15, including extensive issued patents and pending IP patent applications.
Silo Pharma (NASDAQ: SILO) has issued a shareholder letter highlighting progress on its lead assets. The company plans to submit an IND application for SPC-15, an intranasal PTSD treatment, in 2025, followed by Phase 1 clinical trials. SPC-15 has shown promising pre-clinical results for PTSD, stress, and potentially eating disorders.
The company is also advancing SP-26, a ketamine implant for fibromyalgia and chronic pain, with animal testing scheduled for early 2025. Both drugs could qualify for the FDA's streamlined 505(b)(2) regulatory pathway, potentially accelerating approval timelines.
Silo has exclusive global rights to commercialize SPC-15 through a collaboration with Columbia University. The company reports a strong balance sheet with minimal debt as it advances its development programs.
Silo Pharma (NASDAQ: SILO) has initiated a pharmacokinetic (PK) and tolerability study for SP-26, its dissolvable ketamine-based injectable implant targeting chronic pain and fibromyalgia. The three-week non-GLP study, conducted in partnership with AmplifyBio, will evaluate the absorption, distribution, metabolism, and excretion of extended-release ketamine hydrochloride implants in a minipig model. Two different polymer formulations will be tested at various dose levels.
This milestone follows several previous studies including analytical testing, proof-of-concept extrusion trials, manufacturing evaluation, and sterilization tests. SP-26 is being developed as a self-administered, non-opioid therapeutic and aims to be a first-of-its-kind ketamine treatment for chronic pain.
Silo Pharma (SILO) has entered a collaboration agreement with Kymanox to develop a subcutaneous insertion device for SP-26, their ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. The agreement includes initial proof-of-concept design followed by prototype development and feasibility testing to determine optimal tissue insertion depth. Previous testing has confirmed the optimal formulation for SP-26 implants. The company aims to develop SP-26 as a potential first-in-class at-home injectable ketamine-based therapeutic, with preclinical research focusing on FDA safety requirements. Kymanox also serves as Silo's regulatory partner for SPC-15, a treatment for stress-induced affective disorders including PTSD.
Silo Pharma (NASDAQ: SILO) announced positive preclinical study results for SPC-15, a novel dual-action treatment targeting stress-related disorders. The study combined SPC-15, a 5-HT4R agonist, with an NMDAR antagonist, demonstrating enhanced efficacy in treating stress-induced behaviors compared to single-agent treatments. The research showed significant improvements in behavioral outcomes related to severe stress-induced conditions in animal models. The company is developing SPC-15 as an intranasal prophylactic treatment for PTSD and plans to submit an IND for first-in-human trials.